The market for oral anticoagulants has advanced significantly since warfarin was essentially the lone option. Still, in some cases, the use of improved direct oral anticoagulants (DOACs) can provoke ...
An analysis of safety data showed an increased incidence of thrombosis (14.6% vs 6.9%) and thrombosis-related deaths (2.5% vs 0.9%) with Andexxa vs usual care at day 30. The anticoagulant reversal ...
The anticoagulant reversal drug Andexxa was voluntarily pulled from the US market after failing to secure full FDA approval ...
Overall, we have seen an increase in the use of dabigatran after the availability of idarucizumab. We should recognize, however, that we know that all 4 DOACs (direct oral anticoagulants) are ...
NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global anticoagulant reversal drugs market size is estimated to grow by USD 1.27 billion from 2025-2029, ...
Advances in new reversal agents will be key for managing patients treated with DOACs to prevent major bleeding events. Given these recent new guidelines, expert consensus statements, and multiple ...
(MENAFN- EIN Presswire) EINPresswire/ -- The global anticoagulant reversal drugs market is poised for significant expansion over the next decade, driven by increasing use of oral anticoagulants, ...
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of ...
LEIDEN, The Netherlands--(BUSINESS WIRE)--VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of the ...
DUBLIN, Nov. 5, 2019 /PRNewswire/ -- The "Anticoagulant Reversal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026" report has been added to ...
CHICAGO — The Society of Thoracic Surgeons (STS), the Society of Cardiovascular Anesthesiologists (SCA), and the American Society of ExtraCorporeal Technology (AmSECT) have published the first ...
Michael B. Bottorff, PharmD: Fall risk is a major component of a discharge counseling strategy for patients who are newly being started on any anticoagulant, including a DOAC (direct oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback